Day: November 13, 2020

BOISE, Idaho, Nov. 13, 2020 (GLOBE NEWSWIRE) — PCS Edventures!, Inc., (PCSV) a leading provider of K-12 Science, Technology, Engineering and Mathematics (STEM) education programs and drone products, today announced unaudited results of operations for its second quarter of Fiscal Year 2021 which ended on September 30, 2020.Revenue was $0.39 million, which was down 54% from the revenue generated in the same period last year. Net income was ($0.21 million) compared to $0.58 million for the same period last year.Michael Bledsoe, President, commented, “While schools are starting to cautiously go back to in-person learning, the classroom environment has changed. In more instances than not, school supplies and enrichment materials are no longer shared, sometimes by state mandate, with the intention of reducing the risk of COVID-19 transmission....

Verana Health analysis of American Academy of Ophthalmology IRIS®Registry presented in a late-breaking oral sessionReal-world clinical data show significant disease progression over a two-year period in more than 69,000 patients with GA, highlighting the urgent need for treatmentPatients were nearly three times more likely to develop new onset wet age-related macular degeneration (AMD) in an eye with GA when wet AMD had already been detected in the contralateral eyeWALTHAM, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced findings from the largest retrospective database study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The analysis of the American Academy of Ophthalmology...

KING OF PRUSSIA, Pa., Nov. 13, 2020 (GLOBE NEWSWIRE) — Nocopi Technologies, Inc. (OTC Pink: NNUP), a developer of specialty reactive inks used in entertainment, toy and educational products as well as in document and product authentication technologies to combat fraud, today announced results for its third quarter ended September 30, 2020 (Q3’20). Nocopi’s SEC filings are available here, https://bit.ly/35gTldxNocopi Chairman and CEO Michael Feinstein, commented, “Nocopi achieved another quarter of double digit revenue growth driven principally by growing demand for our specialty ink technologies used in toy and entertainment products. Specialty ink sales reached the second highest level in recent periods during the third quarter as our entertainment customers ramped production activity in anticipation of the holiday selling season....

IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced follow-up results of the first 230 patients enrolled in its FLASH study.  FLASH is a real world registry to study the FlowTriever system in intermediate- and high-risk pulmonary embolism (“PE”) patients.  The results were strongly positive.  Just one death (0.4%) was reported at 30 days.  By contrast, the national PERT Consortium® Quality Database recently showed 30-day mortality rates of 25.9% and 6.1% for high- and intermediate-risk PE patients.  In addition, the FLASH Registry showed a readmission rate of 6.7%, compared to the nearly 25% readmission rate shown in the PERT...

BOSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020 at 1:45 pm ET.To access the live webcast presentation, or the subsequent archived recording, please visit the “Investors” section of the Ziopharm website at www.ziopharm.com.About Ziopharm Oncology, Inc. Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm’s pipeline...

West Palm Beach, FL, Nov. 13, 2020 (GLOBE NEWSWIRE) — USA Equities Corp. (OTCQB: USAQ), and its wholly owned subsidiary Medical Practice Income, a company focused on value-based healthcare solutions and physician-directed digital medicine, is proud to announce today, equity research firm, Litchfield Hills Research LLC released its first analyst coverage report on USAQ, rating the Company a “Buy” under its three-tiered (buy-hold-sell) rating system, with a target price of $5.00 per share.As of the end of its last trading day, USAQ’s shares closed at $.62 per share.“We are pleased Litchfield Hills Research initiated research and analyst coverage of USAQ. Litchfield has shown a keen interest in our digital and virtual medicine technologies and will continue to cover our company in the future,” said Troy...

SAN DIEGO, Nov. 13, 2020 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present at the 2020 Jefferies London Virtual Healthcare Conference on Tuesday, November 17, 2020, at 12:35 p.m. ET. The conference will be conducted virtually, and the presentation will be available via https://wsw.com/webcast/jeff141/anab/1804050A live webcast of the presentation will also be available through the investor section of the AnaptysBio website at https://ir.anaptysbio.com/events. A replay of the webcast will be available for 90 days following the event.About AnaptysBioAnaptysBio...

NEW YORK, NY, REHOVAT, ISRAEL, SINGAPORE, Nov. 13, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Todos Medical (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that President & CEO Gerald Commissiong has provided a corporate update to the shareholders:Dear Shareholder,We would like to thank you for continued support as we execute on the vision we laid out in the first half of 2020, transitioning the Company from a cancer and Alzheimer’s-focused R&D diagnostics company into a commercial organization focused on providing comprehensive solutions to address the United States’ biggest challenges in testing, tracing and immune support in...